Respiratory Virus Hospitalization Study (FLU 003 Plus)
Key facts
- Who runs it
- University of Minnesota
- Where
- Boston, Camden, Chattanooga, Chicago, Columbus, Dayton, Detroit, Durham, Milwaukee, New York, Newark, Richmond, Rochester, San Diego, Springfield, The Bronx, and Washington D.C., United StatesSee the 18 sitesAlso in 11 other countries, 45 sites
- Trial code
- Status
- Completed
- People taking part
- 1,000 people, planned
- Started
- Aug 2009
- Ended
- 30 Aug 2024
- Type of study
- Observational, 3 groups
- Record updated
- 21 October 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Be ≥ 18 years of age
- Have been admitted to hospital
- Have a signed informed consent by participant or surrogate/representative
- Have a local diagnosis (confirmed or suspected) of influenza, or of a targeted non-influenza viral respiratory infection*, resulting in (or extending a previous) hospitalization; A list of targeted non-influenza respiratory viruses is maintained on the INSIGHT website
Who cannot take part
- Current imprisonment, or compulsory detention (involuntary incarceration) for treat of a psychiatric or physical illness
Where in United States
Also in 11 other countries, 45 sites
- Brigham and Women's HospitalBoston, United States
- Cooper University HospitalCamden, United States
- University of Tennessee College of MedicineChattanooga, United States
- University of Illinois at ChicagoChicago, United States
- The Ohio State University Medical CenterColumbus, United States
- Miami Valley HospitalDayton, United States
- Henry Ford Health SystemDetroit, United States
- Duke UniversityDurham, United States
- Medical College of WisconsinMilwaukee, United States
- Cornell ID-CRUNew York, United States
- New Jersey Medical School Adult Clinical Research CenterNewark, United States
- Virginia Commonwealth UniversityRichmond, United States
- Mayo ClinicRochester, United States
- UCSD Antiviral Research CenterSan Diego, United States
- Baystate Infectious Diseases Clinical ResearchSpringfield, United States
- Montefiore Medical CenterThe Bronx, United States
- George Washington Medical Faculty AssociatesWashington D.C., United States
- Washington DC VA Medical CenterWashington D.C., United States
About the trial
What the trial wants to find out
Following the sudden and unexpected emergence of influenza A(H1N1)pdm09 (2009 H1N1) virus, this observational study was initiated to estimate rates of morbidity and mortality and to examine predictors of severity among participants with 2009 H1N1 infection. In 2011, as surveillance indicated that 2009 H1N1 virus was co-circulating with other seasonal influenza A and B viruses worldwide, the protocol was expanded to include other influenza A subtypes and influenza B viruses. The current version of the protocol (released in August 2013) further broadens the scope of this observational study. With the recognition that novel respiratory viruses other than novel influenza A viruses, e.g., Middle East Respiratory Syndrome Coronavirus (MERS-CoV), could become prevalent and of major public health importance, the objectives of this protocol have been expanded.
The 3 groups in the trial
- Influenza
Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
- Novel Respiratory Virus-1
MERS-CoV (Middle East Respiratory Syndrome Coronavirus
- Novel Respiratory Virus-2
SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
- Publications
- Metabolite profiles associated with disease progression in influenza infection.PloS one, 2021
- Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018
- Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study.Open forum infectious diseases, 2018
- Record updated
- 21 October 2024